Immunoreactivity assay for α-particle emitting monoclonal antibody constructs

Anthony S. Bonavia, Michael R. McDevitt, Michael J. Curcio, David A. Scheinberg

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Clinical trials using α-particle radiolabeled antibodies require a rapid and reproducible assay of the immunoreactivity of drugs. While live cell assays are typically used to determine the immunoreactive drug fraction, a fixed cell assay may replace the traditional live cell assay and offer the advantages of rapidity, easy availability and consistency for qualifying drugs for preclinical or clinical studies. We have identified optimal cell fixation and immunoreactivity assay conditions and have validated them by performing the fixed-cell assay in clinical trials.

Original languageEnglish (US)
Pages (from-to)470-474
Number of pages5
JournalApplied Radiation and Isotopes
Issue number4
StatePublished - Apr 2006

All Science Journal Classification (ASJC) codes

  • Radiation


Dive into the research topics of 'Immunoreactivity assay for α-particle emitting monoclonal antibody constructs'. Together they form a unique fingerprint.

Cite this